Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarin Corporation PLC Announces Submission Of Supplemental New Drug Application For Novasep As Fourth Vascepa Active Pharmaceutical Ingredient Supplier


Monday, 26 Aug 2013 06:01am EDT 

Amarin Corporation PLC announced the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Novasep Group, S.A.S., through subsidiary Finorga S.A.S., as an additional Vascepa (icosapent ethyl) active pharmaceutical ingredient (API) supplier. Novasep is part of the previously disclosed Slanmhor consortium with which Amarin announced a global supply agreement in 2012. 

Related Company News

Company Quote

1.3
-0.05 -3.70%
19 Sep 2014